NCT05039723View on ClinicalTrials.gov

Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

March 1, 2022

Study Completion Date

July 1, 2022

Conditions
Photoaging
Interventions
DRUG

Radiesse, Xeomin, Belotero

Rejuvenation with Radiesse, Xeomin, Belotero

Trial Locations (1)

19003

Main Line Center for Laser Surgery, Ardmore

All Listed Sponsors
collaborator

Merz North America, Inc.

INDUSTRY

lead

Main Line Center for Laser Surgery

OTHER

NCT05039723 - Xeomin, Radiesse, and Belotero Facial/Neck Rejuvenational | Biotech Hunter | Biotech Hunter